Patent applications published 8 June 2011
Selected patent applications from the weekly European Patents Bulletin
- Pharmaceutical compsn of a radioiodinated benzamide derivative and methods of making the same
Molecular Insight Pharmaceuticals 2328411*
- IAP inhibitors
Tetralogic Pharmaceuticals 2328412*
- Substituted triazolo-pyridazine derivatives
Concert Pharmaceuticals 2328414*
- Compounds, compsns and methods for the treatment of beta-amyloid diseases and synucleinopathies
Proteotech 2328417*
- Sore throat compsns
Reckitt Benckiser Healthcare 2328549*
- Mucoadherents compsns and their use
Incrementha PD&I 2328550*
- Stabilised pharmaceutical sub-micron suspensions and methods of forming same
Alcon Research 2328551*
- Lipid formulations comprising a thiolated antioxidant
Camurus 2328552*
- Corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
The Regents of the University of California 2328553*
- Encapsulation of lipophilic or amphiphilic therapeutic agents in nano-emulsions
Commissariat a l’Energie Atomique et aux Energies Alternatives 2328554*
- Compsns for the treatment of neoplastic diseases
Slotervaart Participaties; Stichting Het Nederlands Kanker Instituut 2328555*
- Formulations containing large-size carrier particles for dry powder inhalation aerosols
STC.UNM 2328556*
- Oral formulations of chemotherapeutic agents
BioAlliance Pharma 2328557*
- Use of sucralose as a granulating agent
McNeil-PPC 2328558*
- Novel antibody formulation
F Hoffmann-La Roche 2328559*
- Pharmaceutical solid preparation
Otsuka Pharmaceutical 2328560*
- Rate modulated delivery of drugs from a a composite delivery system
Adcock Ingram Healthycare 2328561*
- Galenical formulation comprising aliskiren by melt extrusion granulation
Novartis 2328562*
- Solubility enhancing pharmaceutical formulation
Bilgic, Mahmut 2328563*
- Fixed dose combination in form of a bilayered of monolayered tablet of aliskiren and amlodipine
Novartis 2328564*
- An extended release pharmaceutical compsn of entacapone or salts thereof
Wockhardt 2328565*
- Enzyme compsn and application thereof in the treatment of pancreatic insufficiency
DSM IP Assets 2328566*
- Continuous fibre layer comprising an active substance on the basis of biopolymers, the use thereof, an method for the production thereof
BASF 2328567*
- Chewable formulation comprising alginate, bicarbonate and carbonate
Reckitt Benckiser Healthcare 2328568*
- Compsns and methods of treatment comprising ceftaroline
Forest Laboratories Holdings 2328569*
- Method and formulation for treating adverse biological conditions
Livionex 2328570*
- Amino alcohol derivatives for the treatment of demyelinating peripheral neuropathies
Novartis 2328571*
- PKC-activating compounds for the treatment of neurodegenerative diseases
Blanchette Rockefeller Neurosciences Institute 2328572*
- Antibacterial combination therapy for the treatment of gram positive bacterial infections
E-Therapeutics 2328573*
- Treatment of retinal degeneration
University College Cork - National University of Ireland; Consejo Superior De Investigaciones Cientificas 2328574*
- A novel standardised compsn, a method of manufacture and use in the resolution of RNA virus infection
Indus Biotech Private Ltd 2328575*
- Use of NMDA activity enhancers to treat hypersomnia, reduced wakefulness or reduced vigilance
Merck Sharp & Dohme 2328576*
- Noscapine and noscapine analogues and their use in treating infectious disease by tubulin binding inhibition
Emory University 2328578*
- Trioxane dimer sulphur compounds
The Johns Hopkins University 2328579*
- Dabigatran for percutaneous intervention cardiac catheterisation
Boehringer Ingelheim International 2328580*
- Use of dabigatranetexilate for treating patients with pulmonary hypertension
Boehringer Ingelheim International 2328581*
- Transdermal extended-delivery donepezil compsns and methods for using the same
Teikoku Pharma 2328582*
- New therapeutic use of drotaverine
Sanofi-Aventis 2328583*
- Treatment of neurological disorders using huperzine
President and Fellows of Harvard College 2328584*
- Substituted pyradazinone derivatives as histamine-3 (H-3) receptor ligands
Cephalon 2328586*
- Dosage form comprising 1-isopropyl-4-[[4-(tetrahydro-2H-pyran-4-yloxy)phenyl)carbonyl)hexahydro-1H-1,4-diazepine or a salt thereof
Glaxo Group 2328587*
- Treatment of anxiety disorders
NeuroSearch 2328588*
- Treatment of vaginal atrophy in women with tumour pathology risk
Italfarmaco 2328589*
- Topical hydrogel compsn
Nanotherapeutics 2328590*
- Formulations of canfosfamide and their preparations
Telik 2328591*
- Systems and devices for generating nitric oxide
Geno 2328592*
- Uses of mesenchymal stem cells
Cellerix; Consejo Superior De Investigaciones Cientificas 2328594*
- Methods fro stimulating chondrogenesis utilising a potassium channel inhibitor
The University of British Columbia 2328596*
- Bone augmentation utilising muscle derived progenitor compsns in biocompatible matrix, and treatments thereof
University of Pittsburgh of the Commonwealth System of Higher Education 2328596*